KCM
ARRY

Kennedy Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Kennedy Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-28,684
Closed -$1.33M – 759
2019
Q2 		$1.33M Sell
28,684
-168,515
-85% -$4.73M 0.03% 581
2019
Q1 		$4.81M Sell
197,199
-65,971
-25% -$1.37M 0.11% 339
2018
Q4 		$3.75M Sell
263,170
-459,373
-64% -$6.97M 0.09% 400
2018
Q3 		$11M Buy
722,543
+10,581
+1% +$162K 0.2% 149
2018
Q2 		$11.9M Sell
711,962
-51,505
-7% -$819K 0.22% 121
2018
Q1 		$12.5M Buy
763,467
+454,279
+147% +$7.28M 0.24% 113
2017
Q4 		$3.96M Buy
+309,188
New +$3.52M 0.07% 492
2015
Q1 		– Sell
-663,662
Closed -$3.14M – 771
2014
Q4 		$3.14M Buy
+663,662
New +$2.62M 0.06% 495

Other funds holding ARRY

ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Kennedy Capital Management's ARRY Position: Q3 2019 in Review

Kennedy Capital Management sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 28,684 shares — an estimated $1.33M sold.

Kennedy Capital Management first reported a position in ARRY in Q4 2014 and held it in 8 quarters. The position peaked at $12.5M in Q1 2018. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

  • Kennedy Capital Management reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
  • Kennedy Capital Management sold 28,684 Array Biopharma Inc shares in Q3 2019, an estimated $1.33M.
  • Kennedy Capital Management first reported a position in Array Biopharma Inc in Q4 2014 and held it in 8 quarters.
  • Kennedy Capital Management's Array Biopharma Inc position peaked at $12.5M in Q1 2018.
  • 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Kennedy Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.